Study Data from Carnegie Mellon University Update Knowledge of Myeloid Cells (Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide ...)
By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Myeloid Cells are discussed in a new report. According to news reporting out of Pittsburgh, Pennsylvania, by NewsRx editors, research stated, "Superparamagnetic iron-oxide nanoparticles are useful as contrast agents for anatomical, functional and cellular MRI, drug delivery agents, and diagnostic biosensors. Nanoparticles are generally cleared by the reticuloendothelial system (RES), in particular taken up by Kupffer cells in the liver, limiting particle bioavailability and in-vivo applications."
Our news journalists obtained a quote from the research from Carnegie Mellon University, "Strategies that decrease the RES clearance and prolong the circulation residence time of particles can improve the in-vivo targeting efficiency. Intralipid 20.0%, an FDA approved nutritional supplement, was intravenously administered in rats at the clinical dose (2g/kg) 1h before intravenous injection of ultra-small superparamagnetic iron-oxide (USPIO) or micron-sized paramagnetic iron-oxide (MPIO) particles. Blood half-life, monocyte labeling efficiency, and particle biodistribution were assessed by magnetic resonance relaxometry, flow cytometry, inductively-coupled plasma MS, and histology. Pre-treatment with Intralipid resulted in a 3.1-fold increase in USPIO blood half-life and a 2-fold increase in USPIO-labeled monocytes. A 2.5-fold increase in MPIO blood half-life and a 5-fold increase in MPIO-labeled monocytes were observed following Intralipid pre-treatment, with a 3.2-fold increase in mean iron content up to 2.60pg Fe/monocyte. With Intralipid, there was a 49.2% and 45.1% reduction in liver uptake vs. untreated controls at 48h for USPIO and MPIO, respectively. Intralipid pre-treatment significantly decreases initial RES uptake and increases in-vivo circulation and blood monocyte labeling efficiency for nano-and micron-sized superparamagnetic iron-oxide particles."
According to the news editors, the research concluded: "Our findings can have broad applications for imaging and drug delivery applications, increasing the bioavailability of nano-and micron-sized particles for target sites other than the liver."
For more information on this research see: Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. Biochimica Et Biophysica Acta, 2013;1830(6):3447-53 (see also Myeloid Cells).
Our news journalists report that additional information may be obtained by contacting L. Liu, Dept. of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, United States. Additional authors for this research include T.K. Hitchens, Q. Ye, Y. Wu, B. Barbe, D.E. Prior, W.F. Li, F.C. Yeh, L.M. Foley, D.J. Bain and C. Ho.
Keywords for this news article include: Monocytes, Pittsburgh, Immunology, Blood Cells, Pennsylvania, Nanoparticle, United States, Myeloid Cells, Nanotechnology, Bone Marrow Cells, Emerging Technologies, Mononuclear Leukocytes, Hemic and Immune Systems, North and Central America, Mononuclear Phagocyte System.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC